How a bacterial peptide can inhibit harmful fungal infections
Mechanism of Fungal Virulence Inhibition by a Bacterial Peptide
This study is looking at a special substance made by a type of bacteria that might help fight off harmful fungi that can cause infections, especially in people with weakened immune systems, by figuring out how it works and making it even better for future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11045677 on NIH RePORTER |
What this research studies
This research investigates the potential of a peptide called EntV, produced by the bacterium Enterococcus faecalis, to inhibit the virulence of opportunistic fungal pathogens. The study aims to understand the mechanism by which EntV interacts with fungal cells, particularly focusing on its hydrophobic properties that may disrupt the fungi's ability to cause disease. Researchers will modify the peptide to enhance its effectiveness and test these modifications in various animal models to assess their antifungal activity. The ultimate goal is to develop new antifungal therapies that can combat drug-resistant fungal infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by drug-resistant fungal pathogens.
Not a fit: Patients with fungal infections that are not resistant to current antifungal treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal treatments that are effective against resistant fungal infections.
How similar studies have performed: Other research has shown promising results using similar approaches to develop antimicrobial peptides, indicating potential for success in this area.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Lorenz, Michael C — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Lorenz, Michael C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.